CN106604932B - 人白细胞介素-2的免疫刺激单克隆抗体 - Google Patents

人白细胞介素-2的免疫刺激单克隆抗体 Download PDF

Info

Publication number
CN106604932B
CN106604932B CN201580048027.0A CN201580048027A CN106604932B CN 106604932 B CN106604932 B CN 106604932B CN 201580048027 A CN201580048027 A CN 201580048027A CN 106604932 B CN106604932 B CN 106604932B
Authority
CN
China
Prior art keywords
hil
binding
antibody
antigen
mab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580048027.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106604932A (zh
Inventor
奥努尔·波伊曼
娜塔莉亚·阿瑞纳斯拉米雷斯
邹超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of CN106604932A publication Critical patent/CN106604932A/zh
Application granted granted Critical
Publication of CN106604932B publication Critical patent/CN106604932B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580048027.0A 2014-07-10 2015-07-10 人白细胞介素-2的免疫刺激单克隆抗体 Active CN106604932B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176619 2014-07-10
EP14176619.6 2014-07-10
PCT/IB2015/055226 WO2016005950A1 (en) 2014-07-10 2015-07-10 Immune-stimulating monoclonal antibodies against human interleukin-2

Publications (2)

Publication Number Publication Date
CN106604932A CN106604932A (zh) 2017-04-26
CN106604932B true CN106604932B (zh) 2024-12-10

Family

ID=51162588

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580048027.0A Active CN106604932B (zh) 2014-07-10 2015-07-10 人白细胞介素-2的免疫刺激单克隆抗体

Country Status (9)

Country Link
US (2) US10894828B2 (https=)
EP (2) EP3166973B1 (https=)
JP (1) JP7209464B2 (https=)
CN (1) CN106604932B (https=)
AU (1) AU2015287227B2 (https=)
CA (1) CA2954476C (https=)
DK (1) DK3166973T3 (https=)
ES (2) ES2779977T3 (https=)
WO (1) WO2016005950A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003593A (zh) * 2016-01-11 2023-04-25 苏黎世大学 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
GB201621806D0 (en) * 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
WO2018156955A1 (en) * 2017-02-23 2018-08-30 City Of Hope Methods for in vivo expansion of cd8+ t cells and prevention or treatment of gvhd
BR112019019595A2 (pt) * 2017-03-23 2020-04-14 Univ Pennsylvania anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
EP3630825B1 (en) * 2017-05-25 2024-02-14 Institute For Basic Science Anti-human interleukin-2 antibodies and uses thereof
EP3768698B1 (en) 2018-03-19 2025-02-12 MultiVir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CN115768483A (zh) 2020-01-13 2023-03-07 西纳福克斯股份有限公司 抗体与免疫细胞衔接器的缀合物
AU2021221287B2 (en) 2020-02-16 2023-10-05 Aulos Bioscience, Inc Engineered anti-IL-2 antibodies
AR121891A1 (es) * 2020-04-22 2022-07-20 Merck Sharp & Dohme CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO
KR20230048151A (ko) * 2020-08-18 2023-04-10 유니버시타트 취리히 Cd25 편향된 항-il-2 항체
CN116783213A (zh) * 2020-08-18 2023-09-19 苏黎世大学 Cd25偏向的抗il‐2抗体
CN117157107A (zh) 2021-02-08 2023-12-01 西纳福克斯股份有限公司 多功能抗体
WO2023061005A1 (zh) 2021-10-14 2023-04-20 徕特康(苏州)生物制药有限公司 新型抗体-细胞因子融合蛋白及其制备方法和用途
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
CN119912559B (zh) * 2025-01-22 2025-12-26 贵州中医药大学 一种新冠病毒变异株jn.1刺突s蛋白的单链抗体及其应用
CN119775409B (zh) * 2025-03-05 2025-07-11 深圳真实生物医药科技有限公司 靶向sost的抗体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101045923A (zh) * 2006-03-31 2007-10-03 沈阳三生制药有限责任公司 生产一种白细胞介素类似物的方法
CN101189265A (zh) * 2005-06-01 2008-05-28 米克罗麦特股份公司 抗il2抗体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174501B1 (da) 1983-12-23 2003-04-28 Hoffmann La Roche Fremgangsmåde til fremstilling af interleukin-2
JPS62269698A (ja) * 1986-03-17 1987-11-24 エフ．ホフマン　―　ラ　ロシュ　アーゲー Ｉｌ−２蛋白質に対するモノクロ−ナル抗体
ES2308787T3 (es) 1996-08-16 2008-12-01 Schering Corporation Antigenos de superficie de celular de mamiferos; reactivos relacionados.
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2007095643A2 (en) * 2006-02-16 2007-08-23 Nascent Biologics, Inc. Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
PT3042917T (pt) 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189265A (zh) * 2005-06-01 2008-05-28 米克罗麦特股份公司 抗il2抗体
CN101045923A (zh) * 2006-03-31 2007-10-03 沈阳三生制药有限责任公司 生产一种白细胞介素类似物的方法

Also Published As

Publication number Publication date
JP2017525343A (ja) 2017-09-07
US20210230269A1 (en) 2021-07-29
WO2016005950A1 (en) 2016-01-14
JP7209464B2 (ja) 2023-01-20
EP3166973A1 (en) 2017-05-17
CA2954476C (en) 2023-09-19
US20170183403A1 (en) 2017-06-29
US10894828B2 (en) 2021-01-19
EP3166973B1 (en) 2020-02-19
EP3693389C0 (en) 2024-09-04
EP3693389A1 (en) 2020-08-12
AU2015287227A8 (en) 2017-02-16
CN106604932A (zh) 2017-04-26
AU2015287227B2 (en) 2021-02-18
CA2954476A1 (en) 2016-01-14
DK3166973T3 (da) 2020-04-06
ES2989669T3 (es) 2024-11-27
AU2015287227A1 (en) 2017-02-09
EP3693389A9 (en) 2021-04-07
EP3693389B1 (en) 2024-09-04
ES2779977T3 (es) 2020-08-21

Similar Documents

Publication Publication Date Title
CN106604932B (zh) 人白细胞介素-2的免疫刺激单克隆抗体
JP7562528B2 (ja) 抗体及びその用途
CN112955471B (zh) Cd3抗体及其药物用途
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
CN112969476B (zh) 多特异性蛋白分子
CN111744013A (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
CN114502591A (zh) 靶向bcma的抗体、双特异性抗体及其用途
CN112646032A (zh) 靶向bcma的具有人猴交叉的人源化单克隆抗体
CN116554323B (zh) 人源化抗il21抗体的开发和应用
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
WO2023125888A1 (zh) 一种gprc5d抗体及其应用
CN110642951A (zh) 一种抗ca125糖类抗原的高中和活性纳米抗体及其应用
CN117279950A (zh) 一种靶向il-18bp的抗体及其应用
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
WO2024234019A2 (en) Trop2 antibodies
CN120603848A (zh) 三特异性抗原结合分子及其应用
WO2023186100A1 (zh) 抗ror1的抗体及其用途
JP6996825B2 (ja) 修飾ＣκおよびＣＨ１ドメイン
CN118355032A (zh) Bcma抗体及其应用
WO2025146128A1 (zh) 抗liv-1的抗体及其用途
HK40128404A (zh) Trop2抗体
HK40051452A (en) Cd3 antibody and pharmaceutical use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200323

Address after: 71 laimi street, Zurich, ch-8006, Switzerland

Applicant after: UNIVERSITAT ZURICH

Address before: 35 Richter street, Basel, Switzerland

Applicant before: Novartis AG

Applicant before: UNIVERSITAT ZURICH

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant